AbbVie s 1 16 Billion Volume Climbs to 76th Rank as 1 3% Slide Masks Growth from Skyrizi Rinvoq and Strategic Patent Extensions

On September 8, 2025, , ranking 76th in market activity. , reflecting a decline in investor sentiment amid ongoing strategic developments.

AbbVie’s long-term performance has been shaped by its ability to extend patent protections and diversify revenue streams. The company’s flagship drug, Humira, lost exclusive market rights over two decades after its 2003 launch, but its decline has been partially offset by newer therapies. Skyrizi and Rinvoq, both launched in 2019, , . , , as it leverages complex manufacturing processes to prolong exclusivity for injectable treatments.

Strategic spin-offs, such as its separation from Abbott Laboratories in 2013, highlight AbbVie’s focus on mitigating patent-related risks. While Humira’s U.S. biosimilar competition was delayed until 2023 through additional patents, the company now faces pressure to replicate this success with Skyrizi and Rinvoq. Analysts note that maintaining market exclusivity for these newer drugs will be critical to sustaining earnings growth and dividend stability.

The request outlined four key parameters: market universe scope, portfolio rebalancing frequency, weighting methodology, and execution timing. These details determine how the top 500 most-active stocks by volume would be selected, weighted, and traded, with outcomes dependent on assumptions about rebalancing intervals and price execution. Without clarification on these variables, the back-test cannot proceed.